CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SIMICA focuses on advancing the development of innovative protein drug-conjugates for targeted cancer treatment. The project aims to strengthen research collaborations and enhance the capabilities of the Institute of Molecular Medicine through training and networking.
SIMICA will provide IMM with the opportunity to integrate the European circle of research excellence institutions by cementing a sustainable science, technology and innovation network with internationally-leading organisations in the field of protein drug-conjugates.
The strategy of SIMICA is based on science- and innovation-driven clustering, and is focused on the exciting and upcoming area of designing and constructing the next generation of chemically-defined and innovative protein drug-conju…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Austria, Wien
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, 's-Gravenhage (Den Haag)
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom, Cambridge
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
